A Phase 3 Trial of l -Glutamine in Sickle Cell Disease

Abstract excerpt

BACKGROUND: Oxidative stress contributes to the complex pathophysiology of sickle cell disease. Oral therapy with pharmaceutical-grade l-glutamine (USAN, glutamine) has been shown to increase the proportion of the reduced form of nicotinamide adenine dinucleotides in sickle cell erythrocytes, which probably reduces oxidative stress and could result in fewer episodes of sickle cell-related pain. METHODS:...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hemoglobinopathies and Related Disorders
• Share to Metabolism and Genetic Disorders
• Share to Neonatal Health and Biochemistry